Generic name: coagulation factor IX human 100[iU] in 1mL
Dosage form: injection
Medically reviewed on April 6, 2018.
Mononine® is intended for intravenous administration only. It should be reconstituted with the volume of Sterile Water for Injection, USP supplied with the lot, and administered within three hours of reconstitution. Do not refrigerate after reconstitution. After administration, any unused solution and the administration equipment should be discarded.
As a general rule, 1 IU of Factor IX activity per kg can be expected to increase the circulating level of Factor IX by 1% [IU/dL] of normal. The following formula provides a guide to dosage calculations:
|Number of Factor IX||=||Body Weight||×||desired Factor IX||×||1.0 IU/kg|
|IU required (IU)||(in kg)||increase (% or IU/dL normal)||[per IU/dL]|
The amount of Mononine® to be infused, as well as the frequency of infusions, will vary with each patient and with the clinical situation.11,12
As a general rule, the level of Factor IX required for treatment of different conditions is as follows:
|Minor Spontaneous Hemorrhage, Prophylaxis||Major Trauma or Surgery|
|Desired levels of Factor IX for Hemostasis||15-25%
|Initial loading dose to achieve desired level||up to 20-30 IU/kg||up to 75 IU/kg|
|Frequency of dosing||once; repeated in 24 hours if necessary||every 18-30 hours, depending on T1/2 and measured Factor IX levels|
|Duration of treatment||once; repeated if necessary||up to ten days, depending upon nature of insult|
Recovery of the loading dose varies from patient to patient. Doses administered should be titrated to the patient's response. Mononine® administered in doses of ≥75 IU/kg were well tolerated (see CLINICAL PHARMACOLOGY).
In the presence of an inhibitor to Factor IX, higher doses of Mononine® might be necessary to overcome the inhibitor (see PRECAUTIONS). No data on the treatment of patients with inhibitors to Factor IX with Mononine® are available.
For information on rate of administration, see Rate of Administration, below.
- Warm both the diluent and Mononine® in unopened vials to room temperature [not above 37°C (98°F)].
- Remove the caps from both vials to expose the central portions of the rubber stoppers.
- Treat the surface of the rubber stoppers with antiseptic solution and allow them to dry.
- Using aseptic technique, insert one end of the double-end needle into the rubber stopper of the diluent vial. Invert the diluent vial and insert the other end of the double-end needle into the rubber stopper of the Mononine® vial. Direct the diluent, which will be drawn in by vacuum, over the entire surface of the Mononine® cake. (In order to assure transfer of all the diluent, adjust the position of the tip of the needle in the diluent vial to the inside edge of the diluent stopper.) Rotate the vial to ensure complete wetting of the cake during the transfer process.
- Remove the diluent vial to release the vacuum, then remove the double-end needle from the Mononine® vial.
- Gently swirl the vial until the powder is dissolved and the solution is ready for administration. The concentrate routinely and easily reconstitutes within one minute. To assure sterility, Mononine® should be administered within three hours after reconstitution.
- Product should be filtered prior to use as described under Administration. Parenteral drug preparations should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Plastic disposable syringes are recommended with Mononine® solution. The ground glass surfaces of all-glass syringes tend to stick with solutions of this type. Please note, this concentrate is supplied with a SELF-VENTING filter spike.
- Using aseptic technique, attach the vented filter spike to a sterile disposable syringe.
CAUTION: The use of other, non-vented filter needles or spikes without the proper procedure may result in an air lock and prevent the complete transfer of the concentrate.
CAUTION: DO NOT INJECT AIR INTO THE MONONINE® VIAL. The self-venting feature of the vented filter spike precludes the need to inject air in order to facilitate withdrawal of the reconstituted solution. The injection of air could cause partial product loss through the vent filter.
- Insert the vented filter spike into the stopper of the Mononine® vial, invert the vial, and position the filter spike so that the orifice is at the inside edge of the stopper.
- Withdraw the reconstituted solution into the syringe.
- Discard the filter spike. Perform venipuncture using the enclosed winged needle with microbore tubing. Attach the syringe to the luer end of the tubing.
CAUTION: Use of other winged needles without microbore tubing, although compatible with the concentrate, will result in a larger retention of solution within the winged infusion set.
Rate of Administration
The rate of administration should be determined by the response and comfort of the patient; intravenous dosage administration rates of up to 225 IU/minute have been regularly tolerated without incident. When reconstituted as directed, i.e., to approximately 100 IU/mL, Mononine® should be administered at a rate of approximately 2.0 mL per minute.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Mononine (coagulation factor ix)
- Mononine Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews – Add your own review/rating
- Drug class: miscellaneous coagulation modifiers